Mammary analog secretory carcinoma of salivary glands, clinical and pathological insights from a tertiary cancer center in India including literature review
National Journal of Maxillofacial Surgery · 2026-01 · 17 (1) · 56-62
DOI: 10.4103/njms.njms_96_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift National Journal of Maxillofacial Surgery, online erschienen am 30.04.2026. Verfasst von Sunayana Sarkar und 6 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Secretory carcinoma (SC) of salivary gland, a recently described entity resembling secretory carcinoma of breast. It harbors a t(12;15) (p13;q25) translocation resulting in a genetic fusion product ETV6-NTRK3, alternative fusion partners like ETV6-RET, ETV6-MAML3, and ETV6-MET also been described in SC cases lacking classic transcript which aids in targeted therapy. It is characterised by strong immunopositivity for S100, mammaglobin and vimentin.
Aim
As the clinicopathological and treatment outcome data of SC of head and neck sites is limited, we aimed to address the same in this study. Methodology: After ethical approval of the institutional ethics committee, a through a retrospective search of all salivary gland tumors were made from our electronic medical record. Five cases of SC of head and neck were found, out of which 03 cases involved salivary glands, and 02 cases involved buccal mucosa.
Result
The demographic, clinical, histopathological, radiological, treatment and follow up data were aggregated for all patients. Patients age varies from 12- 70 years, with majority occurred in females. All the patients underwent surgical excision and neck was addressed based on clinico-radiological finding, adjuvant therapy in the form of radiotherapy were received in 02 patients in view of higher stage. On average follow up of 06 months, no evidence of disease recurrence noted.
Conclusion
SC is a low grade tumor with favorable outcome and prognosis, histomorphological features with IHC is mandatory for diagnosis. Standard of treatment is surgery, adjuvant treatment based on high risk features, with long term observation is needed.
Zitieren
APA
Sarkar, S., Ranganathan, Y., Mishra, A., Dhal, I., Shukla, S., Nanda, S., & Kapoor, A. (2026). Mammary analog secretory carcinoma of salivary glands, clinical and pathological insights from a tertiary cancer center in India including literature review. National Journal of Maxillofacial Surgery, 17(1), 56-62. https://doi.org/10.4103/njms.njms_96_25
Vancouver
Sarkar S, Ranganathan Y, Mishra A, Dhal I, Shukla S, Nanda S, et al. Mammary analog secretory carcinoma of salivary glands, clinical and pathological insights from a tertiary cancer center in India including literature review. National Journal of Maxillofacial Surgery. 2026;17(1):56-62. doi:10.4103/njms.njms_96_25
BibTeX
@article{Sarkar2026,
author = {Sarkar, Sunayana and Ranganathan, Yamuna and Mishra, Aseem and Dhal, Ipsita and Shukla, Shreya and Nanda, Sambit and Kapoor, Akhil},
title = {Mammary analog secretory carcinoma of salivary glands, clinical and pathological insights from a tertiary cancer center in India including literature review},
journal = {National Journal of Maxillofacial Surgery},
year = {2026},
volume = {17},
number = {1},
pages = {56--62},
doi = {10.4103/njms.njms_96_25}
}
EUVIMED